MASH治疗新进展：miricorilant 1b期研究结果积极，间歇给药方案更具潜力
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology

Miricorilant in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 1b Results Highlight Intermittent Dosing Strategy

This phase 1b study of miricorilant, a selective glucocorticoid receptor modulator, shows significant reductions in liver fat and improvements in liver health markers in patients with presumed metabolic dysfunction-associated steatohepatitis, particularly with intermittent dosing.
Elevated Risk of Inflammatory Bowel Disease Following Anti-CD20 Therapy in Multiple Sclerosis Patients: Insights from a Swedish Population-Based Cohort
Posted inClinical Updates Gastroenterology Neurology

Elevated Risk of Inflammatory Bowel Disease Following Anti-CD20 Therapy in Multiple Sclerosis Patients: Insights from a Swedish Population-Based Cohort

A Swedish cohort study reveals increased risk of inflammatory bowel disease in relapsing-remitting multiple sclerosis patients treated with rituximab compared to other therapies and the general population, underscoring the need for gastrointestinal vigilance during anti-CD20 treatment.
Integrating Therapies for Alcohol Use Disorder in Alcohol-Associated Hepatitis Clinical Trials: Advancing Composite Endpoints for Improved Outcomes
Posted inGastroenterology Internal Medicine news

Integrating Therapies for Alcohol Use Disorder in Alcohol-Associated Hepatitis Clinical Trials: Advancing Composite Endpoints for Improved Outcomes

Alcohol-associated hepatitis (AH) carries high morbidity and mortality, with no approved therapies addressing both liver injury and alcohol misuse. This article explores integrated trial designs using composite endpoints combining liver and alcohol-related outcomes, exemplified by the ITAALD trial.
腹膜细胞学阳性或局限性腹膜转移胃癌的治疗策略优化
Posted inGastroenterology news Oncology

Optimizing Treatment Strategies for Gastric Cancer with Positive Peritoneal Cytology or Localized Peritoneal Metastasis

This article reviews a multicenter study comparing outcomes of different treatment approaches for gastric cancer patients with positive peritoneal cytology (CY1) and/or localized peritoneal metastasis (P1a), highlighting the superior survival with upfront chemotherapy followed by gastrectomy after cytology conversion.